Sunshine Biopharma Inc. has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA lipid nanoparticle (K1.1-mRNA-LNP) product as a novel therapeutic agent for human hepatocellular carcinoma (HCC).